Reducing inequalities with vaccines: New Zealand's MeNZB vaccine initiative to control an epidemic

Journal of Paediatrics and Child Health

Volumn 48, Issue 3, 2012, Pages 193-201

  Lennon, Diana ^a   Reid, Stewart ^b   Stewart, Joanna ^a   Jackson, Catherine ^a   Crengle, Sue ^a   Percival, Teuila ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b Ropata Village Medical Centre   (New Zealand)

Author keywords

epidemic; inequalities; meningococcos; New Zealand; serogroup B; vaccine.

Indexed keywords

MENINGOCOCCUS VACCINE; OUTER MEMBRANE PROTEIN;

ARTICLE; CHILD; CHILD CARE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG LEGISLATION; DRUG TREATMENT FAILURE; EPIDEMIC; HEALTH CARE DISPARITY; HUMAN; IMMUNIZATION; INFECTION CONTROL; MENINGOCOCCOSIS; NEW ZEALAND; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; EPIDEMICS; HEALTH STATUS DISPARITIES; HUMANS; IMMUNIZATION PROGRAMS; INFANT; MENINGITIS, MENINGOCOCCAL; NEISSERIA MENINGITIDIS, SEROGROUP B; NEW ZEALAND; OCEANIC ANCESTRY GROUP; VULNERABLE POPULATIONS; YOUNG ADULT;

EID: 84858437326     PISSN: 10344810     EISSN: 14401754     Source Type: Journal    
DOI: 10.1111/j.1440-1754.2010.01969.x     Document Type: Article

References (54)

1. Craig E, Jackson C, Han DY, NZCYES Steering Committee. Meningococcal Disease. In:, Craig E, ed. Monitoring the Health of New Zealand Children and Young People: Indicator Handbook. Auckland: Paediatric Society of New Zealand, New Zealand Child and Youth Epidemiology Service, 2007; 270-3.
2. Salmond S, Crampton P, Atkinson J, eds. NZDep2006 Index of Deprivation. Wellington: Department of Public Health, University of Otago, 2007.
3. Baker M, McNicholas A, Garrett N, et al,. Household crowding a major risk factor for epidemic meningococcal disease in Auckland children. Pediatr. Infect. Dis. J. 2000; 19: 983-90.
4. Dyet K, Devoy A, McDowell R, Martin D,. New Zealand's epidemic of meningococcal disease described using molecular analysis: implications for vaccine delivery. Vaccine 2005; 23: 2228-30.
5. Martin D, Lopez L, McDowell MC, eds. The Epidemiology of Meningococcal Disease in New Zealand in 2001. Wellington: The Institute of Environmental Science and Research, Ministry of Health, 2002.
6. Martin D, Lopez L, McDowell MC, eds. The Epidemiology of Meningococcal Disease in New Zealand in 2004. The Institute of Environmental Science and Research, Ministry of Health, Wellington, 2004.
7. Lennon D, Voss L, Sinclair J, Heffernan H,. An outbreak of meningococcal disease in Auckland, New Zealand. Pediatr. Infect. Dis. J. 1989; 8: 11-5.
8. Padron FS, Huergo CC, Gill VC, Diaz EM, Valdespino IE, Gotera NG,. Cuban meningococcal BC vaccine: experiences and contributions from 20 years of application. MEDICC Rev. 2007; 9: 16-22.
9. Frasch C, van Alphen L, Holst J, Poolman JT, Rosenqvist E,. Outer membrane protein vesicle vaccines for meningococcal disease. In:, Pollard AJ, Maiden MC, eds. Meningococcal Vaccines: Methods and Protocols. Totowa, NJ: Humana Press, 2001; 81-107.
10. Sierra GV, Campa HC, Varcacel NM, et al,. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann. 1991; 14: 195-207. Discussion 208-110.
11. Bjune G, Hoiby EA, Gronnesby JK, et al,. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. [See comment]. Lancet 1991; 338: 1093-6.
12. Boslego J, Garcia J, Cruz C, et al,. Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease. Vaccine 1995; 13: 821-9.
13. Costa EA,. Effectiveness of meningococcal vaccine in Brazil. Int. J. Epidemiol. 1997; 26: 681-4.
14. Milagres LG, Ramos SR, Sacchi CT, et al,. Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy. Infect. Immun. 1994; 62: 4419-24.
15. Noronha CP, Struchiner CJ, Halloran ME,. Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: a case-control study. Int. J. Epidemiol. 1995; 24: 1050-7.
16. Goldschneider I, Gotschlich EC, Artenstein MS,. Human immunity to the meningococcus. II. Development of natural immunity. J. Exp. Med. 1969; 129: 1327-48.
17. Tappero JW, Lagos R, Ballesteros AM, et al,. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. J. Am. Med. Assoc. 1999; 281: 1520-7.
18. Wenger JD,. Serogroup B meningococcal disease-new outbreaks, new strategies. J. Am. Med. Assoc. 1999; 281: 1541-3.
19. Cartwright K, Morris R, Rumke H, et al,. Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins. Vaccine 1999; 17: 2612-9.
20. de Kleijn ED, de Groot R, Lafeber AB, et al,. Immunogenicity and safety of monovalent p1.7(h), 4 meningococcal outer membrane vesicle vaccine in toddlers: comparison of two vaccination schedules and two vaccine formulations. Vaccine 2000; 19: 1141-8.
21. Lennon D, Gellin BG, Hood D,. Successful vaccine intervention in a group A meningococcal outbreak in Auckland, New Zealand. Pediatr. Infect. Dis. J. 1992; 11: 617-23.
22. Hosking J, Rasanathan K, Mow FC, et al,. Immunogenicity, reactogenicity, and safety of a P1.7b,4 strain-specific serogroup B meningococcal vaccine given to preteens. Clin. Vaccine Immunol. 2007; 14: 1393-9.
23. Jackson C, Lennon D, Sotutu V,. Phase II meningococcal B vesicle vaccine trial in New Zealand infants. Arch. Dis. Child. 2009; 94: 745-51. ADC Published Online First: 6 October 2008. doi:10.1136/adc.2007.132571.
24. Thornton V, Lennon D, Rasanathan K, et al,. Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: beginning of epidemic control. Vaccine 2006; 24: 1395-400.
25. Wong S, Lennon D, Jackson C, et al,. New Zealand epidemic strain meningococcal B outer membrane vesicle vaccine in children aged 16-24 months. Pediatr. Infect. Dis. J. 2007; 26: 345-50.
26. Wong S, Lennon DR, Jackson C, et al,. Immunogenicity and tolerability in infants of a New Zealand epidemic strain meningococcal B outer membrane vesicle vaccine. Pediatr. Infect. Dis. J. 2009; 28: 385-90.
27. Lystad A, Aasen S,. The epidemiology of meningococcal disease in Norway 1975-91. NIPH Ann. 1991; 14: 57-65.
28. Lennon D, Jackson C, Wong S, Horsfall M, Stewart J, Reid S,. Fast tracking the vaccine licensure process to control an epidemic of serogroup B meningococcal disease in New Zealand. Clin. Infect. Dis. 2009; 49: 597-605.
29. Findlow J, Borrow R, Snape MD, et al,. Multicenter, open label, randomised phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin. Infect. Dis. 2010; 51: 1127-37.
30. Zollinger WD, Poolman JT, Maiden MCJ,. Meningococcal serogroup B vaccines: will they live up to expectations? Expert Review of Vaccines; 10: 559-61.
31. Jackson C, Lennon D, Wong S, et al,. Antibody persistence following MeNZB vaccination of adults and children and response to a fourth dose in toddlers. Arch. Dis. Child 2011; 96: 744-51.
32. McNicholas A, Galloway Y, Stehr-Green P, et al,. Post-marketing safety monitoring of a new group B meningococcal vaccine in New Zealand, 2004-2006. Hum. Vaccin. 2007; 3: 196-204.
33. Oster P, Lennon D, O'Hallahan J, Mulholland K, Reid S, Martin D,. MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 2005; 23: 2191-6.
34. Jackson C, Lennon D, Wong S, et al,. Persistence of Immune Response in New Zealand Adults and Children after 3 doses of MeNZB and response to a 4th Dose in Toddlers. Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) September 17-20, 2007. Chicago, United States of America. Poster Presentation. Abstract G-1698.
35. Borrow R, Balmer P, Miller E,. Meningococcal surrogates of protection-serum bactericidal antibody activity. Vaccine 2005; 23: 2222-7.
36. Holst J, Feiring B, Fuglesang JE, et al,. Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. Vaccine 2003; 21: 734-7.
37. Harrison LH,. Vaccine prevention of meningococcal disease: making slow progress. [Comment]. Clin. Infect. Dis. 2006; 43: 1395-7.
38. de Moraes JC, Perkins BA, Camargo MC, et al,. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. [Erratum appears in Lancet 1992 Dec 19-26;340(8834-8835):1554 Note: Gral IM (corrected to Landgraf IM)). Lancet 1992; 340: 1074-8.
39. Ruijne N, Lea RA, O'Hallahan J, Oster P, Martin D,. Understanding the immune responses to the meningococcal strain-specific vaccine MeNZB measured in studies of infants. Clin. Vaccine Immunol. 2006; 13: 797-801.
40. Snape MD, Kelly DF, Salt P, et al,. Serogroup C meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization. [See comment]. Clin. Infect. Dis. 2006; 43: 1387-94.
41. Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME,. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. [See comment]. Lancet 2004; 364: 365-7.
42. Perkins B, Jonsdottir K, Briem H, et al,. Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland. J. Infect. Dis. 1998; 177: 683-91.
43. Feiring B, Fuglesang J, Oster P, et al,. Persisting immune responses indicating long-term protection after booster dose with meningococcal group B outer membrane vesicle vaccine. Clin. Vaccine Immunol. 2006; 13: 790-6.
44. Galloway Y, Stehr-Green P, McNicholas A, O'Hallahan J,. Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years. Int. J. Epidemiol. 2009; 38: 413-8.
45. Kelly C, Arnold R, Galloway Y, O'Hallahan J,. A prospective study of the effectiveness of New Zealand meningococcal B vaccine. Am. J. Epidemiol. 2007; 166: 817-23.
46. Kelly C, Arnold R, Galloway Y, O'Hallahan J,. The authors reply-re: 'a prospective study of the effectiveness of the New Zealand meningococcal B vaccine'. Am. J. Epidemiol. 2008; 167: 1141-2.
47. Lennon D, Stewart J, Crengle S,. Re: 'a prospective study of the effectiveness of the New Zealand meningococcal B vaccine'. Am. J. Epidemiol. 2008; 167: 1140-1.
48. Murphy TV, White KE, Pastor P, et al,. Declining incidence of Haemophilus influenzae type b disease since introduction of vaccination. J.A.M.A. 1993; 269: 246-8.
49. O'Hallahan J, McNicholas A, Galloway Y, O'Leary E, Roseveare C,. Delivering a safe and effective strain-specific vaccine to control an epidemic of group B meningococcal disease. N.Z. Med. J. 2009; 122: 48-59.
50. Lennon D,. The role of MeNZB vaccination in controlling the New Zealand meningococcal epidemic. N.Z. Med. J. 2008; 121: 110-2.
51. Pizza M, Scarlato V, Masignani V, et al,. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 2000; 287: 1816-20.
52. Voss L, Lennon D, Okesene-Gafa K, Ameratunga S, Martin D,. Invasive pneumococcal disease in a pediatric population, Auckland, New Zealand. Pediatr. Infect. Dis. J. 1994; 13: 873-8.
53. Blackmore T, Buchan G, Grant C, et al,. New Vaccines. In: New Zealand Ministry of Health, eds. Immunisation Handbook 2006. Wellington: New Zealand Ministry of Health, 2006; 351-3.
54. Priest P, Sadler L, Sykes P, Marshall R, Peters J, Crengle S,. Determinants of inequalities in cervical cancer stage at diagnosis and survival in New Zealand. Cancer Causes Control 2010; 21: 209-14.